Navigation Links
Cipher Appeals FDA's Decision On CIP-TRAMADOL ER
Date:12/4/2007

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Dec. 4 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has appealed the position taken by the U.S. Food and Drug Administration (FDA) in its approvable letter for CIP-TRAMADOL ER, using the FDA's Formal Dispute Resolution process. Cipher received an approvable letter from the FDA in May 2007 pertaining to its New Drug Application (NDA) for CIP-TRAMADOL ER, the Company's extended-release formulation of tramadol.

"After further dialogue with the FDA over the past several months on the questions raised in the approvable letter, we have determined that the formal dispute resolution process is the most appropriate path forward at this time to achieve final regulatory approval for this product," said Larry Andrews, President and CEO of Cipher.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by ProEthic Pharmaceuticals under the label Lipofen(TM). In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotretinoin.

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit http://www.cipherpharma.com.

Forward-Looking Statements

Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. Some forward-looking statements may be identified by words like "may", "will", "anticipate", "estimate", "expect", "intend", or "continue" or the negative thereof or similar variations. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company's pipeline; changes in government regulation or regulatory approval processes; government and third-party payer reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel. All forward-looking statements presented herein should be considered in conjunction with such filings. The Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.


'/>"/>
SOURCE Cipher Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cipher reports third quarter fiscal 2007 results
2. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
3. NBME Appeals Massachusetts Judges Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
6. Microarray provides 3 genomic guides to breast cancer treatment decisions
7. Spectranetics to Appeal Decision in Patent Litigation
8. Canadas government funds $1.6M in modern geography to support public health decisions
9. Parents participation in medical decisions linked to self-efficacy
10. Decision-making by residents on-call has miniscule negative impact on patient care
11. Political decisions harming cancer treatment in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... MD (PRWEB) , ... February 08, 2016 , ... ... is excited to share this important news! AHCC and the Home Health and ... Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to address ...
(Date:2/8/2016)... ... 2016 , ... The schedule is now online for the largest ... which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to ... causes of chronic illness in children. , Very recent articles have cited 1 child ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company ... retinal disease, announced today agreements for the clinical supply ... manufacture material at multiple sites, including Slough (UK), Visp ... --> Retinal diseases, such as age-related ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... Vestagen Technical Textiles, Inc., a medical technology ... and other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as ... joining Vestagen,s Board of Directors. ® , ... technologies that combines fluid repellent, antimicrobial and breathability properties. ...
Breaking Medicine Technology: